<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426176</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-29</org_study_id>
    <nct_id>NCT03426176</nct_id>
  </id_info>
  <brief_title>The Interaction Between Oxytocin and Serotonin</brief_title>
  <official_title>The Interaction Between Oxytocin and Serotonin on the Social-emotional Brain Networks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study aims to explore whether there is an interaction between oxytocin and serotonin in
      the regulation of emotion-based behavior by using a between-subject randomized double blind
      pharmacological fMRI design during which 4 groups of healthy male subjects will receive
      combinations of oxytocin nasal-spray (versus placebo) and acute tryptophan depletion (ATD,
      versus placebo)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Convergent evidence from animal models and human studies suggests that both, serotonin and
      oxytocin are important regulators of social emotional behavior. Evidence is emerging that
      both systems interact in this domain. To determine the interaction of both systems on human
      social behavior, the present study aims to combine a randomized placebo-controlled
      administration of modulators of both systems (Oxytocin nasal-spray and acute tryptophan
      depletion, ATD) and their combination within a pharmaco-fMRI experiment. To determine effects
      on the neural networks engaged in social emotional processing, healthy male subjects will
      receive single doses of oxytocin (24IU) versus placebo and ATD (75.2g) versus placebo before
      fMRI measures of emotion perception and resting state will be acquired. To control for
      potential effects of pre-medication personality traits as well as effects of medicines on
      mood, subjects will be administered pre-treatment assessing relevant personality traits and
      post-treatment assessments of mood.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neural processing during the emotion processing as assessed via fMRI</measure>
    <time_frame>6h after treatment</time_frame>
    <description>fMRI BOLD indices of neural processing in emotion related brain regions will be compared between the treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural processing during the resting state as assessed via fMRI</measure>
    <time_frame>6h after treatment</time_frame>
    <description>Resting state activity in the emotional brain networks will be compared between the treatment groups</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>male oxytocin and ATD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male subjects receiving oxytocin and ATD treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male oxytocin and placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male subjects receiving oxytocin and ATD-placebo treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male placebo and ATD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male subjects receiving oxytocin placebo and ATD treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>male subjects receiving oxytocin placebo and ATD placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin nasal spray</intervention_name>
    <description>intranasal administration of oxytocin (24 IU)</description>
    <arm_group_label>male oxytocin and ATD group</arm_group_label>
    <arm_group_label>male oxytocin and placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal placebo treatment (placebo-control for oxytocin)</intervention_name>
    <description>intranasal administration of placebo nasal spray</description>
    <arm_group_label>male placebo and ATD group</arm_group_label>
    <arm_group_label>male placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATD treatment</intervention_name>
    <description>oral administration of ATD (75.2g) (Acute Tryptophan Depletion)</description>
    <arm_group_label>male oxytocin and ATD group</arm_group_label>
    <arm_group_label>male placebo and ATD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo treatment (placebo-control for ATD)</intervention_name>
    <description>oral administration of a tryptophan-balanced mixture (78.2g)</description>
    <arm_group_label>male oxytocin and placebo group</arm_group_label>
    <arm_group_label>male placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  health subjects without past or current psychiatric or neurological disorders

          -  Right-handedness

        Exclusion Criteria:

          -  History of head injury;

          -  Medical or psychiatric illness.

          -  High blood pressure, general cardio-vascular alterations

          -  History of drug or alcohol abuse or addiction.

          -  Allergy against medications or general strong allergies

          -  Sleep disorders.

          -  Visual or motor impairments
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Becker, Dr.</last_name>
    <phone>86-28-61830988</phone>
    <email>ben_becker@gmx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Life Science and Technology</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>611731</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihua Zhao</last_name>
      <email>zarazhao.uestc@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Benjamin Becker</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>acute tryptophan depletion</keyword>
  <keyword>emotion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

